Skip to main content
. 2016 Oct 24;7(46):76261–76273. doi: 10.18632/oncotarget.12842

Table 1. Descriptions of demographic, clinical and pathological characteristics for the 260 patients included in this study.

Characteristic Total (n=260)
n %
Age (year)
  Median (P25, P75) 61 (52, 67)
Sex
  Male 201 77.3
  Female 59 22.7
Tumor location
  CE/UTE 28 10.8
  MTE 173 66.5
  LTE 59 22.7
Tumor length (cm)
  Median (P25, P75) 4.0 (3.0, 4.5)
Primary tumor (pT)
  pT1 30 11.5
  pT2 44 16.9
  pT3 164 63.1
  pT4 22 8.5
Regional lymph nodes (pN)
  pN0 119 45.8
  pN1 67 25.1
  pN2 54 20.8
  pN3 20 7.7
Distant metastasis (M)
  M0 260 100
  M1 0 0
Histologicgrade (pG)
  pG1 79 30.4
  pG2 148 56.9
  pG3 18 6.9
Tumor stage (pTNM)
  0 3 1.2
  IA 7 2.7
  IB 28 10.8
  IIA 37 14.2
  IIB 52 20.0
  IIIA 61 23.5
  IIIB 37 14.2
  IIIC 35 13.5
LVI
  Yes 71 27.3
  No 189 72.7
PNI
  Yes 62 23.8
  No 198 76.2
Type of lymphadenectomy
  3-FLND 153 58.8
  2-FLND 107 41.2
Residual tumor (R)
  Rx 5 1.9
  R0 251 96.5
  R1 4 1.5
Anastomotic leak
  Yes 52 20.0
  No 191 73.5
Postoperative infection*
  Yes 124 47.7
  No 119 45.8
Chemotherapy
  Yes 74 28.5
  No 186 71.5
Radiotherapy
  Yes 59 22.7
  No 201 77.3
Harvested lymph nodes (HLNs)
  Median (P25, P75) 35 (25, 46)
Positive lymph nodes (PLNs)
  Median (P25, P75) 1 (0, 3)

CE, cervical esophagus; UTE, upper thoracic esophagus; MTE, middle thoracic esophagus; LTE, lower thoracic esophagus; LVI, lymphovascular invasion; PNI, perineural invasion; 3-FLND, three-field lymph node dissection; 2-FLND, two-field lymph node dissection.